Skip to main content
Mark Tyson, MD, Urology, Phoenix, AZ, Mayo Clinic Hospital

MarkDTysonMD

Urology Phoenix, AZ

Surgical Oncology

Physician

Dr. Tyson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Tyson's full profile

Already have an account?

Education & Training

  • Mayo Clinic College of Medicine and Science (Arizona)
    Mayo Clinic College of Medicine and Science (Arizona)Residency, Urology, 2011 - 2015
  • Mayo Clinic College of Medicine and Science
    Mayo Clinic College of Medicine and ScienceInternship, Transitional Year, 2010 - 2011
  • Geisel School of Medicine at Dartmouth
    Geisel School of Medicine at DartmouthClass of 2010
  • University of Arizona
    University of ArizonaB.S., Molecular and Cellular Biology, Magna Cum Laude, 2002 - 2006

Certifications & Licensure

  • NM State Medical License
    NM State Medical License 2022 - 2026
  • CO State Medical License
    CO State Medical License 2022 - 2025
  • ID State Medical License
    ID State Medical License 2022 - 2024
  • AZ State Medical License
    AZ State Medical License 2011 - 2024
  • CA State Medical License
    CA State Medical License 2022 - 2024
  • NV State Medical License
    NV State Medical License 2022 - 2023
  • TN State Medical License
    TN State Medical License 2015 - 2018
  • American Board of Urology Urology

Awards, Honors, & Recognition

  • Chief Debate Winner American Urological Association, 2015
  • 3rd Place, Oral Presentation - Academic Excellence Day, Department of Education Administration Mayo Clinic Arizona, 2014
  • Scholarship Recipient Mayo Foundation, 2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Medicare Accountable Care Organization Enrollment and Appropriateness of Cancer Screening  
    Matthew J Resnick, David F Penson, Mark D Tyson, JAMA
  • Medicare Accountable Care Organization Enrollment and Appropriateness of Cancer Screening  
    David F. Penson, Matthew J Resnick, Mark D. Tyson, JAMA
  • Reply  
    Tyson MD, Humphreys MR, Castle EP, Parker AS, Urology, 1/1/2013
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Functional Analysis of Patient Outcomes Following Different Surgical Interventions for Benign Prostate Hyperplasia Through the Administration of an Independent Survey
    Tyson MD, American Urological Association, New Orleans, LA, 1/1/2015
  • Radical Prostatectomy Trends in the United States: 1998-2011
    Tyson MD, American Urological Association, New Orleans, LA, 1/1/2015
  • Change in CO2 Predicts Hospital Readmission for Failure to Thrive after Radical Cystectomy
    Tyson MD, Society for Urologic Oncology, 1/1/2014
  • Join now to see all

Lectures

  • Assessment of treatment patterns of nonmuscle invasive bladder cancer patients in privately insured patients. 
    2019 ASCO Annual Meeting - 6/1/2019
  • Mayo Clinic Benefits and Other Financial Musings 
    Mayo Clinic, Phoenix, AZ - 1/1/2015
  • The Impact of Training on the Perioperative and Intermediate Functional Outcomes After Holmium Laser Enucleation of the Prostate 
    New Orleans, LA - 1/1/2015
  • Join now to see all

Press Mentions

  • The TAR-200 Device in Muscle-Invasive Bladder Cancer: Safety, Efficacy, and Future Prospects - Mark D. Tyson, II
    The TAR-200 Device in Muscle-Invasive Bladder Cancer: Safety, Efficacy, and Future Prospects - Mark D. Tyson, IIMay 23rd, 2023
  • Novel Device May Be Safe, Effective Chemotherapy Delivery System for Patients with Muscle-Invasive Bladder Cancer Who Are Unfit for Standard Therapy
    Novel Device May Be Safe, Effective Chemotherapy Delivery System for Patients with Muscle-Invasive Bladder Cancer Who Are Unfit for Standard TherapyApril 12th, 2023
  • Sustained-Release Chemotherapy Gives New Option for Frail Patients with Invasive Bladder Cancer
    Sustained-Release Chemotherapy Gives New Option for Frail Patients with Invasive Bladder CancerApril 7th, 2023
  • Join now to see all

Hospital Affiliations